Showing results (561-570 of 666) with videos related to
Sort By:
Pageof 67
Clinical Pharmacology and Therapeutics|February 8, 2014
Genetic risk factors for major bleeding in patients treated with warfarin in a community settingJ A Roth, D Boudreau, M M Fujii, et al.The Annals of Thoracic Surgery|July 1, 1989
Determinants of perioperative morbidity and mortality after pneumonectomyR Wahi, M J McMurtrey, L F DeCaro, et al.Journal of the American College of Cardiology|November 1, 1991
Exacerbation of ventricular arrhythmias during the postoperative period after implantation of an automatic defibrillatorS G Kim, J D Fisher, S Furman, et al.Journal of the American College of Cardiology|June 1, 1991
Benefits of implantable defibrillators are overestimated by sudden death rates and better represented by the total arrhythmic death rateS G Kim, J D Fisher, S Furman, et al.International Journal of Cancer|November 14, 1997
Novel combination therapy for human colon cancer with adenovirus-mediated wild-type p53 gene transfer and DNA-damaging chemotherapeutic agentN Ogawa, T Fujiwara, S Kagawa, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 1999
Recombinant adenovirus expressing wild-type p53 is antiangiogenic: a proposed mechanism for bystander effectM Nishizaki, T Fujiwara, T Tanida, et al.Oncogene|March 4, 2000
Overexpression of the wild-type p53 gene inhibits NF-kappaB activity and synergizes with aspirin to induce apoptosis in human colon cancer cellsJ Shao, T Fujiwara, Y Kadowaki, et al.American Journal of Clinical Oncology|March 10, 2001
Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junctionI I Schnirer, R Komaki, J C Yao, et al.Carcinogenesis|September 1, 1995
Higher lung cancer risk for younger African-Americans with the Pro/Pro p53 genotypeX Jin, X Wu, J A Roth, et al.The Journal of Experimental Medicine|October 1, 1983
Lymphokine-activated killer cell phenomenon. III. Evidence that IL-2 is sufficient for direct activation of peripheral blood lymphocytes into lymphokine-activated killer cellsE A Grimm, R J Robb, J A Roth, et al.Pageof 67